How do you pay?

How to pay the least

Ask for the cash price

Yeztugo

We didn’t find one.

  1. Ask your pharmacy for Yeztugo’s cash price, and one or two other pharmacies too.
  2. Yeztugo’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP). Or call 1-800-226-2056.

See if you qualify 

Compare every option

Question
Brand nameYeztugo
Authorized genericlenacapavir
Regular genericlenacapavir
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Yeztugo?
The original
–
–

Brand nameThe maker’s card

Gilead Advancing Access Co-pay Savings Program

Savings card from Gilead Sciences

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on yeztugo.com 

Or call 1-800-226-2056.

In the maker’s words

“If you qualify, you could pay as little as $0 for your prescription through the co-pay program.”

From the maker’s offer on yeztugo.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Yeztugo itself, from the same company, sold without the brand name, and usually for less. For now Yeztugo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

YEZTUGO, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO.

Source: the FDA label for Yeztugo (Gilead Sciences, Inc.), August 11, 2026. Full label on DailyMed 

Good to know